Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2015 - 2026)

Teva Pharmaceutical Industries' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $555.0 million for Q1 2026.

• Quarterly Accumulated Expenses rose 17.09% year-over-year to $555.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $555.0 million (up 17.09% YoY) and the FY2025 annual result came in at $2.7 billion, up 330.61% from the prior year.
• Accumulated Expenses was $555.0 million for Q1 2026 at Teva Pharmaceutical Industries, down from $2.7 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.0 billion in Q3 2025 and bottomed at $474.0 million in Q1 2025.
• A 5-year average of $1.8 billion and a median of $2.2 billion in 2022 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 330.61% in 2025, while the deepest fall reached 82.97% in 2025.
• Teva Pharmaceutical Industries' Accumulated Expenses stood at $2.2 billion in 2022, then tumbled by 71.59% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then soared by 330.61% to $2.7 billion in 2025, then sank by 79.34% to $555.0 million in 2026.
• Business Quant data shows TEVA's Accumulated Expenses at $555.0 million in Q1 2026, $2.7 billion in Q4 2025, and $3.0 billion in Q3 2025.